Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
88.01 (1y: +39%)
Market Cap 245.42 B P/E(ttm) 23.90
Enterprise Value 239.86 B P/B 3.80
JNJ- NYSE (USA)
Johnson & Johnson
  • Currently 2.5/5
Business Predictability Rank: 2.5-Star
Back Testing Results:
Average gain of all 2.5-Star stocks: 7.3% per year.
% of Stocks that are in still loss if held for 10yrs: 18%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$88.01
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry		 vs
history
Cash to Debt 1.305
JNJ's Cash to Debt is ranked lower than
61% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.36 vs. JNJ: 1.305 )
JNJ' s 10-Year Cash to Debt Range
Min: 0.62   Max: 6.01
Current: 1.31
0.62
6.01
Equity to Asset 0.112
JNJ's Equity to Asset is ranked lower than
87% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.52 vs. JNJ: 0.112 )
JNJ' s 10-Year Equity to Asset Range
Min: 0.11   Max: 0.44
Current: 0.11
0.11
0.44
Interest Coverage 33.9
JNJ's Interest Coverage is ranked lower than
71% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10000.00 vs. JNJ: 33.9 )
JNJ' s 10-Year Interest Coverage Range
Min: 34   Max: No Debt
Current: 33.9
F-Score: 5
Z-Score: 4.85
M-Score: -2.51
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry		 vs
history
Operating margin (%) 23.60
JNJ's Operating margin (%) is ranked higher than
84% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.70 vs. JNJ: 23.60 )
JNJ' s 10-Year Operating margin (%) Range
Min: 21.6   Max: 27.1
Current: 23.6
21.6
27.1
Net-margin (%) 16.1
JNJ's Net-margin (%) is ranked higher than
84% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.20 vs. JNJ: 16.1 )
JNJ' s 10-Year Net-margin (%) Range
Min: 14.9   Max: 21.7
Current: 16.1
14.9
21.7
ROE (%) 16.7
JNJ's ROE (%) is ranked higher than
89% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.20 vs. JNJ: 16.7 )
JNJ' s 10-Year ROE (%) Range
Min: 16.7   Max: 30.5
Current: 16.7
16.7
30.5
ROA (%) 8.9
JNJ's ROA (%) is ranked higher than
86% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.00 vs. JNJ: 8.9 )
JNJ' s 10-Year ROA (%) Range
Min: 8.5   Max: 17.9
Current: 8.9
8.5
17.9
ROC (Joel Greenblatt) (%) 73.70
JNJ's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.40 vs. JNJ: 73.70 )
JNJ' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 57   Max: 114.4
Current: 73.7
57
114.4
Revenue Growth (%) 1.9
JNJ's Revenue Growth (%) is ranked higher than
80% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.20 vs. JNJ: 1.9 )
JNJ' s 10-Year Revenue Growth (%) Range
Min: 1   Max: 10.2
Current: 1.9
1
10.2
EBITDA Growth (%) 1.4
JNJ's EBITDA Growth (%) is ranked higher than
86% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.35 vs. JNJ: 1.4 )
JNJ' s 10-Year EBITDA Growth (%) Range
Min: 1.2   Max: 13.2
Current: 1.4
1.2
13.2
EPS Growth (%) -3.2
JNJ's EPS Growth (%) is ranked higher than
68% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.20 vs. JNJ: -3.2 )
JNJ' s 10-Year EPS Growth (%) Range
Min: -6.5   Max: 12.5
Current: -3.2
-6.5
12.5
ยป JNJ's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

JNJ Guru Trades in Q2 2012

George Soros 155,000 sh (New)
Paul Tudor Jones 586,500 sh (New)
Louis Moore Bacon 302,600 sh (New)
Steven Cohen 2,478,370 sh (+1069.88%)
Pioneer Investments 1,957,071 sh (+156.52%)
Jim Simons 6,723,100 sh (+113.87%)
Tweedy Browne Global Value 865,835 sh (+63.86%)
Chuck Royce 40,690 sh (+61.4%)
Ray Dalio 329,793 sh (+48.49%)
Manning & Napier Advisors, Inc 511,435 sh (+35.25%)
Tweedy Browne 4,398,798 sh (+18.1%)
Jeff Auxier 99,006 sh (+13.24%)
Donald Yacktman 8,092,590 sh (+7.77%)
First Pacific Advisors 1,950,200 sh (+7.32%)
John Rogers 103,361 sh (+7.26%)
PRIMECAP Management 14,494,287 sh (+7.21%)
Steven Romick 1,870,000 sh (+6.55%)
HOTCHKIS & WILEY 5,633,818 sh (+3.57%)
Mario Gabelli 501,866 sh (+2.54%)
Jeremy Grantham 26,152,844 sh (+0.97%)
Robert Olstein 106,000 sh (+0.95%)
Jean-Marie Eveillard 1,615,660 sh (+0.91%)
Bill Frels 1,701,837 sh (+0.25%)
Richard Pzena 5,787 sh (+0.17%)
Brian Rogers 4,633,000 sh (unchged)
Prem Watsa 5,947,300 sh (unchged)
John Hussman 1,751,000 sh (unchged)
Murray Stahl 35,262 sh (unchged)
Michael Price 45,000 sh (unchged)
Richard Snow 3,200 sh (unchged)
Richard Perry 466,051 sh (unchged)
Diamond Hill Capital 2,261,237 sh (unchged)
Vanguard Health Care Fund 4,500,000 sh (unchged)
Meridian Funds 7,885 sh (unchged)
Paul Tudor Jones 228,100 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Tom Gayner 562,295 sh (-0.05%)
Ken Fisher 10,705,335 sh (-0.52%)
Dodge & Cox 43,641 sh (-0.75%)
James Barrow 16,687,262 sh (-1.38%)
Ruane Cunniff 17,223 sh (-7.32%)
Tom Russo 11,781 sh (-9.17%)
Joel Greenblatt 7,777 sh (-28.8%)
Mark Hillman 40,706 sh (-47.07%)
Warren Buffett 10,333,128 sh (-64.39%)
Chris Davis 2,765,454 sh (-73.47%)
» More
Q3 2012

JNJ Guru Trades in Q3 2012

Sarah Ketterer 245,050 sh (New)
George Soros 2,568,800 sh (+1557.29%)
Pioneer Investments 4,920,069 sh (+151.4%)
Chuck Royce 47,665 sh (+17.14%)
HOTCHKIS & WILEY 5,861,432 sh (+4.04%)
Donald Yacktman 8,387,771 sh (+3.65%)
Tom Gayner 582,095 sh (+3.52%)
Bill Frels 1,727,280 sh (+1.5%)
First Pacific Advisors 1,950,700 sh (+0.03%)
Richard Snow 3,200 sh (unchged)
Yacktman Fund 3,500,000 sh (unchged)
Dodge & Cox 43,641 sh (unchged)
Meridian Funds 7,885 sh (unchged)
Robert Olstein 106,000 sh (unchged)
Steven Romick 1,870,000 sh (unchged)
Yacktman Focused Fund 3,100,000 sh (unchged)
Michael Price 45,000 sh (unchged)
Brian Rogers 4,633,000 sh (unchged)
Richard Perry 466,051 sh (unchged)
Vanguard Health Care Fund 4,500,000 sh (unchged)
Prem Watsa 5,947,300 sh (unchged)
Paul Tudor Jones 135,500 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Joel Greenblatt Sold Out
Murray Stahl 35,152 sh (-0.31%)
Ken Fisher 10,657,625 sh (-0.45%)
PRIMECAP Management 14,276,187 sh (-1.5%)
Tweedy Browne 4,329,942 sh (-1.57%)
Jeff Auxier 97,306 sh (-1.72%)
James Barrow 16,345,969 sh (-2.05%)
Diamond Hill Capital 2,192,154 sh (-3.06%)
John Rogers 100,042 sh (-3.21%)
Ruane Cunniff 16,587 sh (-3.69%)
Jeremy Grantham 25,048,851 sh (-4.22%)
Manning & Napier Advisors, Inc 487,125 sh (-4.75%)
Jean-Marie Eveillard 1,523,260 sh (-5.72%)
Richard Pzena 5,328 sh (-7.93%)
Mario Gabelli 425,944 sh (-15.13%)
Ray Dalio 269,693 sh (-18.22%)
Mark Hillman 31,340 sh (-23.01%)
John Hussman 1,251,000 sh (-28.56%)
Tom Russo 5,415 sh (-54.04%)
Louis Moore Bacon 132,600 sh (-56.18%)
Steven Cohen 363,942 sh (-85.32%)
Chris Davis 316,768 sh (-88.55%)
Warren Buffett 492,028 sh (-95.24%)
Paul Tudor Jones 8,300 sh (-98.58%)
Jim Simons 46,600 sh (-99.31%)
» More
Q4 2012

JNJ Guru Trades in Q4 2012

Joel Greenblatt 20,867 sh (New)
Paul Tudor Jones 157,600 sh (+1798.8%)
Manning & Napier Advisors, Inc 4,713,227 sh (+867.56%)
Jim Simons 201,900 sh (+333.26%)
Sarah Ketterer 355,150 sh (+44.93%)
Mario Gabelli 441,808 sh (+3.72%)
Bill Frels 1,777,667 sh (+2.92%)
Tom Gayner 592,495 sh (+1.79%)
Jean-Marie Eveillard 1,540,760 sh (+1.15%)
Tweedy Browne 4,367,061 sh (+0.86%)
George Soros 2,589,022 sh (+0.79%)
First Pacific Advisors 1,953,900 sh (+0.16%)
Donald Yacktman 8,395,706 sh (+0.09%)
Meridian Funds 7,885 sh (unchged)
Michael Price 45,000 sh (unchged)
Yacktman Focused Fund 3,100,000 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Robert Olstein 106,000 sh (unchged)
Vanguard Health Care Fund 4,500,000 sh (unchged)
Brian Rogers 4,633,000 sh (unchged)
Richard Snow 3,200 sh (unchged)
Steven Romick 1,870,000 sh (unchged)
Yacktman Fund 3,500,000 sh (unchged)
Jeremy Grantham 23,162,101 sh (unchged)
Richard Pzena Sold Out
Steven Cohen Sold Out
Prem Watsa 5,941,600 sh (-0.1%)
PRIMECAP Management 14,223,787 sh (-0.37%)
Jeff Auxier 96,941 sh (-0.38%)
James Barrow 16,265,164 sh (-0.49%)
Chuck Royce 46,700 sh (-2.02%)
Ruane Cunniff 16,200 sh (-2.33%)
Ken Fisher 10,394,670 sh (-2.47%)
HOTCHKIS & WILEY 5,663,067 sh (-3.38%)
Pioneer Investments 4,680,974 sh (-4.86%)
Diamond Hill Capital 2,072,912 sh (-5.44%)
Chris Davis 294,586 sh (-7%)
Murray Stahl 31,962 sh (-9.07%)
Dodge & Cox 39,325 sh (-9.89%)
Richard Perry 388,897 sh (-16.55%)
John Rogers 80,642 sh (-19.39%)
Mark Hillman 25,172 sh (-19.68%)
Warren Buffett 327,100 sh (-33.52%)
Ray Dalio 170,693 sh (-36.71%)
John Hussman 501,750 sh (-59.89%)
Tom Russo 715 sh (-86.8%)
Louis Moore Bacon 4,600 sh (-96.53%)
» More
Q1 2013

JNJ Guru Trades in Q1 2013

Richard Pzena 10,075 sh (New)
Bruce Kovner 150,000 sh (New)
Steven Cohen 4,466 sh (New)
Jim Simons 1,641,200 sh (+712.88%)
John Rogers 99,722 sh (+23.66%)
Yacktman Focused Fund 3,800,000 sh (+22.58%)
Donald Yacktman 9,740,875 sh (+16.02%)
Yacktman Fund 4,050,000 sh (+15.71%)
Manning & Napier Advisors, Inc 5,173,111 sh (+9.76%)
Mario Gabelli 463,668 sh (+4.95%)
Bill Frels 1,844,286 sh (+3.75%)
Jeremy Grantham 23,958,058 sh (+3.44%)
James Barrow 16,479,099 sh (+1.32%)
Richard Snow 3,230 sh (+0.94%)
Jeff Auxier 97,577 sh (+0.66%)
Jean-Marie Eveillard 1,541,960 sh (+0.08%)
Tom Gayner 592,850 sh (+0.06%)
Brian Rogers 4,633,000 sh (unchged)
Michael Price 45,000 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Prem Watsa 5,941,600 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Richard Perry 388,897 sh (unchged)
Meridian Funds 7,885 sh (unchged)
Steven Romick 1,870,000 sh (unchged)
Paul Tudor Jones Sold Out
Diamond Hill Capital Sold Out
Louis Moore Bacon Sold Out
First Pacific Advisors 1,951,500 sh (-0.12%)
Tweedy Browne 4,355,404 sh (-0.27%)
Dodge & Cox 39,125 sh (-0.51%)
Chuck Royce 45,900 sh (-1.71%)
George Soros 2,534,022 sh (-2.12%)
Chris Davis 287,663 sh (-2.35%)
Ken Fisher 10,133,469 sh (-2.51%)
Murray Stahl 30,952 sh (-3.16%)
Pioneer Investments 4,532,388 sh (-3.17%)
PRIMECAP Management 13,647,387 sh (-4.05%)
Vanguard Health Care Fund 4,268,100 sh (-5.15%)
Mark Hillman 23,319 sh (-7.36%)
Ruane Cunniff 14,765 sh (-8.86%)
Tom Russo 640 sh (-10.49%)
HOTCHKIS & WILEY 5,000,039 sh (-11.71%)
Sarah Ketterer 295,550 sh (-16.78%)
Robert Olstein 88,000 sh (-16.98%)
Ray Dalio 76,293 sh (-55.3%)
Joel Greenblatt 8,669 sh (-58.46%)
John Hussman 2,650 sh (-99.47%)
» More
» Details

Insider Trades

Latest Guru Trades with JNJ

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2013-03-31 Reduce -99.47%0.93%$70.1 - $81.53 $ 88.0116%2650
Yacktman Focused Fund 2013-03-31 Add 22.58%0.78%$70.1 - $81.53 $ 88.0116%3800000
Donald Yacktman 2013-03-31 Add 16.02%0.57%$70.1 - $81.53 $ 88.0116%9740875
Yacktman Fund 2013-03-31 Add 15.71%0.53%$70.1 - $81.53 $ 88.0116%4050000
Ray Dalio 2013-03-31 Reduce -55.3%0.07%$70.1 - $81.53 $ 88.0116%76293
Joel Greenblatt 2013-03-31 Reduce -58.46%0.05%$70.1 - $81.53 $ 88.0116%8669
John Rogers 2013-03-31 Add 23.66%0.03%$70.1 - $81.53 $ 88.0116%99722
Richard Pzena 2013-03-31 New Buy0.01%$70.1 - $81.53 $ 88.0116%10075
John Hussman 2012-12-31 Reduce -59.89%1.26%$67.97 - $72.52 $ 88.0126%501750
Joel Greenblatt 2012-12-31 New Buy0.09%$67.97 - $72.52 $ 88.0126%20867
Ray Dalio 2012-12-31 Reduce -36.71%0.09%$67.97 - $72.52 $ 88.0126%170693
Warren Buffett 2012-12-31 Reduce -33.52%0.02%$67.97 - $72.52 $ 88.0126%327100
Richard Pzena 2012-12-31 Sold Out 0.0031%$67.97 - $72.52 $ 88.0126%0
George Soros 2012-09-30 Add 1557.29%2.73%$67.21 - $69.55 $ 88.0129%2568800
Mark Hillman 2012-09-30 Reduce -23.01%1.13%$67.21 - $69.55 $ 88.0129%31340
Warren Buffett 2012-09-30 Reduce -95.24%0.9%$67.21 - $69.55 $ 88.0129%492028
John Hussman 2012-09-30 Reduce -28.56%0.63%$67.21 - $69.55 $ 88.0129%1251000
Chris Davis 2012-09-30 Reduce -88.55%0.38%$67.21 - $69.55 $ 88.0129%316768
Donald Yacktman 2012-09-30 Add 3.65%0.12%$67.21 - $69.55 $ 88.0129%8387771
Joel Greenblatt 2012-09-30 Sold Out 0.04%$67.21 - $69.55 $ 88.0129%0
Mark Hillman 2012-06-30 Reduce -47.07%2.02%$61.94 - $67.65 $ 88.0137%40706
Tweedy Browne 2012-06-30 Add 18.1%1.61%$61.94 - $67.65 $ 88.0137%4398798
Warren Buffett 2012-06-30 Reduce -64.39%1.61%$61.94 - $67.65 $ 88.0137%10333128
Chris Davis 2012-06-30 Reduce -73.47%1.03%$61.94 - $67.65 $ 88.0137%2765454
Donald Yacktman 2012-06-30 Add 7.77%0.26%$61.94 - $67.65 $ 88.0137%8092590
George Soros 2012-06-30 New Buy0.15%$61.94 - $67.65 $ 88.0137%155000
Ray Dalio 2012-06-30 Add 48.49%0.11%$61.94 - $67.65 $ 88.0137%329793
PRIMECAP Management 2012-06-30 Add 7.21%0.11%$61.94 - $67.65 $ 88.0137%14494287
Joel Greenblatt 2012-06-30 Reduce -28.8%0.02%$61.94 - $67.65 $ 88.0137%7777
Premium More recent guru trades are included for Premium Members only!!

Ratios

vs
industry		 vs
history
P/E(ttm) 23.90
JNJ's P/E(ttm) is ranked higher than
73% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 29.76 vs. JNJ: 23.90 )
JNJ' s 10-Year P/E(ttm) Range
Min: 10.5   Max: 34.05
Current: 23.9
10.5
34.05
P/B 3.80
JNJ's P/B is ranked lower than
53% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. JNJ: 3.80 )
JNJ' s 10-Year P/B Range
Min: 2.71   Max: 8.59
Current: 3.8
2.71
8.59
P/S 3.64
JNJ's P/S is ranked lower than
60% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.32 vs. JNJ: 3.64 )
JNJ' s 10-Year P/S Range
Min: 2.16   Max: 5.99
Current: 3.64
2.16
5.99
PFCF 20.80
JNJ's PFCF is ranked higher than
75% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.89 vs. JNJ: 20.80 )
JNJ' s 10-Year PFCF Range
Min: 10.29   Max: 31.92
Current: 20.8
10.29
31.92
EV-to-EBIT 14.9
JNJ's EV-to-EBIT is ranked higher than
74% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.70 vs. JNJ: 14.9 )
JNJ' s 10-Year EV-to-EBIT Range
Min: 8.4   Max: 24.7
Current: 14.9
8.4
24.7
PEG 16
JNJ's PEG is ranked lower than
63% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.23 vs. JNJ: 16 )
JNJ' s 10-Year PEG Range
Min: 1.13   Max: 45.69
Current: 16
1.13
45.69
Shiller P/E 19.7
JNJ's Shiller P/E is ranked higher than
87% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 30.12 vs. JNJ: 19.7 )
JNJ' s 10-Year Shiller P/E Range
Min: 12.9   Max: 30.41
Current: 19.7
12.9
30.41

Dividend & Buy Back

vs
industry		 vs
history
Dividend Yield 2.77
JNJ's Dividend Yield is ranked higher than
94% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.36 vs. JNJ: 2.77 )
JNJ' s 10-Year Dividend Yield Range
Min: 1.1   Max: 3.84
Current: 2.77
1.1
3.84
Dividend Payout 0.6623
JNJ's Dividend Payout is ranked higher than
86% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.86 vs. JNJ: 0.6623 )
JNJ' s 10-Year Dividend Payout Range
Min: 0.37   Max: 0.65
Current: 0.66
0.37
0.65
Dividend growth (3y) 5.6
JNJ's Dividend growth (3y) is ranked higher than
94% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -0.95 vs. JNJ: 5.6 )
JNJ' s 10-Year Dividend growth (3y) Range
Min: 5.6   Max: 12.5
Current: 5.6
5.6
12.5
Yield on cost (5-Year) 4.04
JNJ's Yield on cost (5-Year) is ranked higher than
96% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.42 vs. JNJ: 4.04 )
JNJ' s 10-Year Yield on cost (5-Year) Range
Min: 1.59   Max: 5.54
Current: 4.04
1.59
5.54
Share Buyback Rate -0.2
JNJ's Share Buyback Rate is ranked higher than
93% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -2.00 vs. JNJ: -0.2 )
JNJ' s 10-Year Share Buyback Rate Range
Min: 1.5   Max: -1.9
Current: -0.2

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 20.1
JNJ's Price/Net Current Asset Value is ranked higher than
83% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.20 vs. JNJ: 20.1 )
JNJ' s 10-Year Price/Net Current Asset Value Range
Min: 16.2   Max: 36.7
Current: 20.1
16.2
36.7
Price/Tangible Book 18
JNJ's Price/Tangible Book is ranked higher than
96% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.40 vs. JNJ: 18 )
JNJ' s 10-Year Price/Tangible Book Range
Min: 7   Max: 18.4
Current: 18
7
18.4
Price/DCF (Projected) 1.5
JNJ's Price/DCF (Projected) is ranked higher than
77% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. JNJ: 1.5 )
JNJ' s 10-Year Price/DCF (Projected) Range
Min: 1   Max: 2.1
Current: 1.5
1
2.1
Price/Median PS Value 1
JNJ's Price/Median PS Value is ranked higher than
82% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.70 vs. JNJ: 1 )
JNJ' s 10-Year Price/Median PS Value Range
Min: 0.8   Max: 1.6
Current: 1
0.8
1.6
Price/Graham Number 4.4
JNJ's Price/Graham Number is ranked higher than
89% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.30 vs. JNJ: 4.4 )
JNJ' s 10-Year Price/Graham Number Range
Min: 2   Max: 4.2
Current: 4.4
2
4.2
Earnings Yield (Greenblatt) 6.70
JNJ's Earnings Yield (Greenblatt) is ranked higher than
80% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.90 vs. JNJ: 6.70 )
JNJ' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.1   Max: 11.9
Current: 6.7
4.1
11.9
Forward Rate of Return (Yacktman) 5.8
JNJ's Forward Rate of Return (Yacktman) is ranked higher than
70% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.82 vs. JNJ: 5.8 )
JNJ' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 3.1   Max: 19.2
Current: 5.8
3.1
19.2

Business Description

Johnson & Johnson was incorporated in the State of New Jersey in 1887. The Company is engaged in the research and development, manufacture and sale of a range of products in the health care field. It is a holding company, which has more than 250 operating companies conducting business in virtually all countries of the world. The Company's operating companies are organized into three business segments: Consumer, Pharmaceutical and Medical Devices and Diagnostics. The Consumer segment includes a range of products used in the baby care, skin care, oral care, wound care and women's health care fields, as well as nutritional and over-the-counter pharmaceutical products. The Baby Care franchise includes the JOHNSON'S Baby line of products. Major brands in the Skin Care franchise include the AVEENO; CLEAN & CLEAR; JOHNSON'S Adult; NEUTROGENA; RoC; LUBRIDERM; Beijing Dabao Cosmetics Co., Ltd.; and Vendome product lines. The Oral Care franchise includes the LISTERINE and REACH oral care lines of products. Major brands in the Women"s Health franchise are the CAREFREE Pantiliners and STAYFREE sanitary protection products. The nutritional and over-the-counter lines include SPLENDA, No Calorie Sweetener; the family of TYLENOL acetaminophen products; SUDAFED cold, flu and allergy products; ZYRTEC allergy products; MOTRIN IB ibuprofen products; and PEPCID AC Acid Controller from Johnson & Johnson Merck Consumer Pharmaceuticals Co. The Pharmaceutical segment includes products in the following therapeutic areas: anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, urology and virology. Key products in the Pharmaceutical segment include: REMICADE a biologic approved for the treatment of Crohn's disease, ankylosing spondylitis, psoriasis, psoriatic arthritis, ulcerative colitis, and use in the treatment of rheumatoid arthritis; TOPAMAX approved for adjunctive and monotherapy use in epilepsy, as well as for the prophylactic treatment of migraines; PROCRIT biotechnology-derived product that stimulates red blood cell production; RISPERDAL oral a medication that treats the symptoms of schizophrenia, bipolar mania and irritability associated with autistic behavior in indicated patients. RISPERDAL CONSTA, a long-acting injectable, and INVEGATM Extended-Release tablets, for the treatment of schizophrenia; LEVAQUIN and FLOXIN, both in the anti-infective field; CONCERTA, a product for the treatment of attention deficit hyperactivity disorder; ACIPHEX/PARIET, a proton pump inhibitor co-marketed with Eisai Inc.; and DURAGESIC/Fentanyl Transdermal a treatment for chronic pain that offers a novel delivery system. The Medical Devices and Diagnostics segment includes a range of products distributed to wholesalers, hospitals and retailers, used mainly in the professional fields by physicians, nurses, therapists, hospitals, diagnostic laboratories and clinics. In a
Company Website
SEC Reports
Industry: Drug Manufacturers - Major
Compare:GSK, PFE, RHHBY, NVS, ABT
Traded in other countries:JNJ.Germany
ยป More Articles for JNJ

Headlines

Articles On GuruFocus.com
20 Mega Caps and Their Dividend Payments and Which to Consider May 17 2013 
Why would I not sell dividend stocks even after a 1000% gain? May 15 2013 
Richard Pzena Buys 5 New Stocks May 14 2013 
6 Dividend Stocks to Beat the Wall Street Giants May 14 2013 
First Quarter 2013: Top and Bottom Performing Dividend Stocks May 07 2013 
Donald Yacktman Buys Microsoft, Coca-Cola Co, CH Robinson, Sells H&R Block, Research in Motion May 02 2013 
A Disciplined Approach to Dividend Stocks May 01 2013 
Four Attractively Priced Dividend Stocks Boosting Distributions Apr 29 2013 
Where is the Larger Bubble: the S&P 500 Index or U.S. Treasuries? Apr 26 2013 
Many of My Dividend Growth Stocks Have Become Overvalued, What Do I Do Now? Apr 25 2013 

More From Our Partners
Stock Market News for May 14, 2013 - Market News May 14 2013 - ZACKS

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial